📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-21 17:10
136 analysed today
FollowTelegram
136
Today
149,537
All-time analysed
42,893
Positive
6,653
Negative
91,318
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
19 announcements match the current filters (relevance ≥ 5).
SRPL Sells Immovable Property for ₹16.76 Cr to KSP Auto and Forge
Shree Ram Proteins Limited (SRPL) has completed the sale of its immovable property located at Gondal, Rajkot, Gujarat for a consideration of ₹16.76 crore on September 21, 2026. The buyer is KSP Auto and Forge Private Limited, an unrelated third party. The transaction represents a substantial liquidity event for SRPL, whose current market capitalization is approximately ₹10 crore against total debt of ₹37 crore. The sale follows shareholder approval secured via postal ballot on September 9, 2026.
Confidence: HIGH
What changedSRPL completed the monetization and sale deed execution of its land property in Gondal, Rajkot for ₹16.76 crore.
Why it mattersThe ₹16.76 crore proceeds exceed the company's current market cap of ₹10 crore, offering critical liquidity to a distressed business that generated ₹0 TTM revenue and holds ₹37 crore in debt.
Sale consideration: Rs. 16,76,30000/-Sale value vs Market Cap: ~167%Completion date: September 21, 2026Postal ballot approval date: September 9, 2026
📅 Short termProvides immediate liquidity relief, which may help address near-term default risks and statutory obligations.
📈 Long termWhile asset sales ease immediate insolvency pressure, core solvent extraction operations remain stalled with zero revenue across recent quarters.
⚠ Risk flags
- Core operations remain inactive (₹0 revenue)
- Significant outstanding debt burden of ₹37 Cr
- Asset disposal reduces the fixed asset base of the company
Key Highlights
Executed and registered sale deed on September 21, 2026, for consideration of ₹16,76,30,000
Buyer identified as non-promoter entity KSP Auto and Forge Private Limited
Shareholder approval was received via postal ballot on September 9, 2026
Board originally approved the enabling resolution on August 10, 2026
👀 What to Watch
Monitor upcoming quarterly filings to see whether proceeds are deployed toward debt reduction (total debt ₹37 Cr) or settlement of statutory dues.
SRPL Sells Immovable Property for ₹16.76 Cr to KSP Auto and Forge
Shree Ram Proteins Limited (SRPL) has completed the sale of its immovable property located at Gondal, Rajkot, Gujarat for a consideration of ₹16.76 crore on September 21, 2026. The buyer is KSP Auto and Forge Private Limited, an unrelated third party. The transaction represents a substantial liquidity event for SRPL, whose current market capitalization is approximately ₹10 crore against total debt of ₹37 crore. The sale follows shareholder approval secured via postal ballot on September 9, 2026.
Confidence: HIGH
What changedSRPL completed the monetization and sale deed execution of its land property in Gondal, Rajkot for ₹16.76 crore.
Why it mattersThe ₹16.76 crore proceeds exceed the company's current market cap of ₹10 crore, offering critical liquidity to a distressed business that generated ₹0 TTM revenue and holds ₹37 crore in debt.
Sale consideration: Rs. 16,76,30000/-Sale value vs Market Cap: ~167%Completion date: September 21, 2026Postal ballot approval date: September 9, 2026
📅 Short termProvides immediate liquidity relief, which may help address near-term default risks and statutory obligations.
📈 Long termWhile asset sales ease immediate insolvency pressure, core solvent extraction operations remain stalled with zero revenue across recent quarters.
⚠ Risk flags
- Core operations remain inactive (₹0 revenue)
- Significant outstanding debt burden of ₹37 Cr
- Asset disposal reduces the fixed asset base of the company
Key Highlights
Executed and registered sale deed on September 21, 2026, for consideration of ₹16,76,30,000
Buyer identified as non-promoter entity KSP Auto and Forge Private Limited
Shareholder approval was received via postal ballot on September 9, 2026
Board originally approved the enabling resolution on August 10, 2026
👀 What to Watch
Monitor upcoming quarterly filings to see whether proceeds are deployed toward debt reduction (total debt ₹37 Cr) or settlement of statutory dues.
SRPL Reports Q1 FY27 Net Loss of ₹6.36 Cr on Nil Operational Revenue; OTS Default Disclosed
Shree Ram Proteins Limited reported zero revenue from operations for the quarter ended June 30, 2026, alongside a net loss of ₹6.36 crore (compared to a loss of ₹1.82 crore in Q1 FY26). The company disclosed severe financial distress, noting it failed to pay the second OTS installment of ₹3.76 crore and the final installment of ₹18.56 crore to Union Bank of India after paying ₹2.43 crore upfront. Additionally, the bank sold secured assets worth ₹3.82 crore on May 18, 2026, reflecting severe working capital and liquidity shortfalls against an existing total debt burden of ₹37 crore.
Confidence: HIGH
What changedSRPL approved Q1 FY27 unaudited results and FY26 audited results, revealing ongoing operational paralysis and failure to honor its bank OTS plan.
Why it mattersWith zero revenue, negative net worth erosion, and a defaulted OTS, the company faces material uncertainty regarding its ability to continue as a going concern.
Q1 FY27 Revenue from Operations: ₹NilQ1 FY27 Net Loss: ₹6.36 crDefaulted OTS 2nd Installment: ₹3.76 crDefaulted OTS Final Installment: ₹18.56 crLender Asset Sale Value: ₹3.82 cr
📅 Short termNegative sentiment is likely to persist given the zero top-line, widening quarterly losses, and lender asset enforcement actions.
📈 Long termHigh insolvency risk; operations cannot restart without resolving working capital deficits, statutory dues, and secured debt settlements.
⚠ Risk flags
- Default on One-Time Settlement (OTS) with Union Bank of India
- Material uncertainty over going concern status
- Lender enforcement and liquidation of secured assets
- Persistent zero operational revenue and depleted liquidity
Key Highlights
Q1 FY27 revenue from operations stood at ₹Nil with other income of ₹1.40 crore.
Net loss expanded to ₹6.36 crore for Q1 FY27 versus ₹1.82 crore in Q1 FY26.
Defaulted on Union Bank of India OTS installments of ₹3.76 crore and final due of ₹18.56 crore.
Union Bank of India sold company property/security worth ₹3.82 crore on May 18, 2026.
Reported basic and diluted EPS of ₹-0.30 for the quarter ended June 30, 2026.
👀 What to Watch
Track lender recovery actions or insolvency proceedings by Union Bank of India and monitor whether any preferential issue is approved to inject liquidity.
SRPL Reports Q1 FY27 Net Loss of ₹6.36 Cr on Zero Operational Revenue; OTS Defaults Persist
Shree Ram Proteins reported zero revenue from operations for the quarter ended June 30, 2026, consistent with prior quarters of halted business activity. The company recorded a net loss of ₹6.36 crore for the quarter, driven primarily by finance costs of ₹7.21 crore. Notes to the financial results disclose a critical default on a One-Time Settlement (OTS) with Union Bank of India, having failed to pay instalments of ₹3.76 crore and ₹18.56 crore. Furthermore, the bank sold assets/security worth ₹3.82 crore in May 2026, underlining acute insolvency and going-concern risks.
Confidence: HIGH
What changedSRPL disclosed its audited FY26 and unaudited Q1 FY27 financial results, reporting continued zero operating revenue alongside default disclosures on its bank loan settlement.
Why it mattersThe company has an unserviced debt burden (₹37 crore) relative to its market cap of ₹10 crore, with defaulted OTS terms and asset sales signaling extreme insolvency risk.
Q1 FY27 Revenue from Operations: ₹0.00Q1 FY27 Net Loss: ₹6.36 croreFinance Costs (Q1 FY27): ₹7.21 croreDefaulted OTS Final Instalment: ₹18.56 croreDefaulted Debt vs Market Cap: ~185% of Market Cap (₹18.56 Cr / ₹10 Cr)
📅 Short termNegative sentiment is likely to persist as operational shutdown continues and lenders exercise legal recovery actions.
📈 Long termGoing-concern viability remains in severe doubt without a massive capital infusion or formal debt restructuring.
⚠ Risk flags
- Going-concern risk flagged by auditors
- Default on Union Bank of India OTS instalments totaling over ₹22 crore
- Zero operational revenue indicating halted plant operations
Key Highlights
Revenue from operations stood at ₹0 for Q1 FY27, with total income at ₹1.40 crore (purely other income)
Net loss for Q1 FY27 reached ₹6.36 crore, deteriorated by finance costs of ₹7.21 crore
Company defaulted on OTS instalments of ₹3.76 crore and ₹18.56 crore due to Union Bank of India after paying ₹2.43 crore upfront
Union Bank of India sold security assets worth ₹3.82 crore on May 18, 2026
Basic and diluted EPS for the quarter was -₹0.30 per equity share
👀 What to Watch
Track lender recovery proceedings and potential insolvency resolution or liquidation steps by Union Bank of India given the defaulted OTS terms.
SRPL Shareholders Approve Disposal of Whole or Substantially Whole of Company Undertaking
Shree Ram Proteins Limited has submitted voting results and a scrutinizer's report for a postal ballot approving a Special Resolution under Section 180(1)(a) of the Companies Act, 2013, to sell, lease, or otherwise dispose of the whole or substantially the whole of the undertaking of the company. A total of 17,675,333 votes were cast, with 17,656,004 votes (99.89%) in favor and 19,329 votes against. The approval comes as the distressed company posted zero TTM revenue and holds Rs 37 Cr in debt against a market capitalization of Rs 10 Cr.
Confidence: HIGH
What changedShareholders have formally approved the enabling resolution granting the Board authority to sell, lease, or dispose of the whole or substantially the whole of the company's undertaking.
Why it mattersWith TTM revenue at Rs 0 Cr, continuous quarterly net losses, and Rs 37 Cr in debt, monetizing or selling the undertaking is a critical restructuring or survival move for the company.
Total valid votes polled: 17675333Votes in favour (%): 99.8906%Votes against (%): 0.1094%Debt vs Market Cap: 3.7x (Rs 37 Cr debt / Rs 10 Cr m-cap)
📅 Short termMarkets will watch for execution announcements detailing what specific plant, assets, or undertaking are being disposed of and whether proceeds will clear outstanding dues.
📈 Long termDisposing of the core undertaking may lead to corporate restructuring, total change in business activity, or liquidation given prolonged lack of operational revenue.
⚠ Risk flags
- Complete disposal of primary operational assets or business undertaking
- Extreme financial distress with zero revenue and negative net worth erosion
- Low promoter holding of 4.08%
Key Highlights
Special Resolution passed to sell, lease, or dispose of the whole or substantially the whole undertaking under Section 180(1)(a)
Approval passed with 99.89% of polled votes in favor (17,656,004 votes)
Total votes polled stood at 17,675,333 shares, representing 8.2513% of total share capital
Voting period ran from August 11, 2026 to September 09, 2026 with 41,240 shareholders on record
👀 What to Watch
Track subsequent exchange filings for the exact transaction details, buyer identity, asset valuation, and terms regarding the proposed sale or lease of the company's undertaking.
SRPL Shareholders Approve Sale of Undertaking and Capital Raise via QIP
Shree Ram Proteins Limited has submitted a revised scrutinizer report for its EOGM held on March 05, 2026. Shareholders approved Resolution 1 for the sale of the company's undertaking as a material related party transaction, with 7,714,361 valid votes in favour (100% of valid votes) and 8,733,679 invalid votes. Shareholders also approved Resolution 2 to raise capital via Qualified Institutions Placement (QIP) with 16,433,040 votes in favour and 15,000 against. The company is facing severe distress with zero TTM revenue, Rs 37 Cr in debt, and a market capitalization of Rs 10 Cr.
Confidence: HIGH
What changedShareholders formally approved the sale of the company's operating undertaking as a material related-party transaction and authorized equity capital raising via QIP.
Why it mattersWith TTM revenue at Rs 0 Cr, negative net worth trajectory, and Rs 37 Cr debt, selling assets and raising QIP capital are critical survival and debt-restructuring measures.
Votes in favour (Sale of undertaking): 7714361 votesInvalid votes (Sale of undertaking): 8733679 votesVotes in favour (QIP raise): 16433040 votesVotes against (QIP raise): 15000 votesMarket Cap: Rs 10 CrTotal Debt: Rs 37 Cr
📅 Short termScrutinizer report confirmation removes procedural uncertainty around shareholder assent, but disclosures on transaction execution and QIP pricing remain pending.
📈 Long termThe sale of the undertaking indicates an exit or structural downsizing of current manufacturing operations, while any QIP could cause heavy dilution for a micro-cap with a 4.08% promoter stake.
⚠ Risk flags
- Related-party transaction risk regarding valuation and transfer terms in the sale of the undertaking.
- Significant potential equity dilution from QIP given the low market cap of Rs 10 Cr.
- Large block of invalid votes (8.73M votes) on the asset sale resolution.
Key Highlights
Resolution 1 (Sale of undertaking as material RPT) passed with 7,714,361 votes in favour (100% of valid votes cast).
A total of 8,733,679 votes across 7 members were declared invalid for the asset sale resolution.
Resolution 2 (QIP capital raise) approved with 16,433,040 votes in favour and 15,000 votes against.
Voting was conducted via remote e-voting and EOGM e-voting for members registered as of February 26, 2026.
👀 What to Watch
Track subsequent exchange disclosures regarding the exact valuation and buyer details for the undertaking sale, along with the issue price and dilution quantum for the proposed QIP.
SRPL Posts ₹6.36 Cr Q1 Loss; Plant Auctioned at ₹3.82 Cr Post Debt Default
Shree Ram Proteins reported zero revenue from operations for both Q1 FY27 (quarter ended June 30, 2026) and the full year FY26. Net loss for Q1 FY27 widened to ₹6.36 Cr (compared to ₹1.82 Cr in Q1 FY26), heavily impacted by finance costs of ₹7.21 Cr. The company defaulted on its One-Time Settlement (OTS) with Union Bank of India after missing scheduled installments of ₹3.76 Cr and ₹18.56 Cr. Consequently, the lender auctioned the company's plant and machinery on May 18, 2026 for ₹3.82 Cr, leading the statutory auditors to issue an adverse opinion with material going-concern uncertainty.
Confidence: HIGH
What changedReported audited FY26 and unaudited Q1 FY27 financials showing zero revenue, while disclosing the bank-forced auction of its plant and machinery.
Why it mattersThe auction of key manufacturing assets and persistent OTS defaults severely jeopardize operational viability, placing the company's going-concern status under extreme risk.
Revenue from Operations (Q1 FY27): ₹0.00Net Loss (Q1 FY27): ₹636.40 lakhsNet Loss (FY26): ₹1,010.85 lakhsOverdue OTS Installments: ₹2,232.50 lakhsPlant & Machinery Auction Value: ₹382.00 Lakh
📅 Short termNegative sentiment is likely to persist given the adverse audit report, asset liquidation by lenders, and lack of core revenue generation.
📈 Long termSevere survival risk; core manufacturing operations are halted following the auction of plant and machinery unless substantial recapitalization occurs.
⚠ Risk flags
- Going concern uncertainty with adverse auditor opinion
- Auction of entire plant and machinery by secured lender
- Default on One-Time Settlement (OTS) and loan covenants
- Zero operational revenue
Key Highlights
Revenue from operations remained at ₹0.00 for Q1 FY27 and FY26.
Q1 FY27 net loss stood at ₹636.40 lakhs, compared to ₹181.94 lakhs in the prior-year period.
Defaulted on OTS terms after paying ₹242.50 lakhs upfront, missing installments of ₹376.25 lakhs and ₹1,856.25 lakhs.
Lender auctioned the entire plant and machinery on May 18, 2026 for ₹382.00 lakhs.
Auditors issued an adverse opinion highlighting pervasive going-concern risks and unverified assets/inventories.
👀 What to Watch
Track lender recovery actions, potential insolvency (IBC) proceedings, and corporate disclosures regarding debt restructuring or capital raising.
SRPL Reports Q1 Loss of ₹6.36 Cr with Zero Operations; Bank Auctions Entire Plant & Machinery
Shree Ram Proteins reported a standalone net loss of ₹6.36 Cr for the quarter ended June 30, 2026, widening from a loss of ₹1.82 Cr in the year-ago period, with zero revenue from operations. Total expenses stood at ₹7.76 Cr, primarily driven by finance costs of ₹7.21 Cr. The company disclosed that it failed to honor its One-Time Settlement (OTS) terms with Union Bank of India, defaulting on installments of ₹3.76 Cr and ₹18.56 Cr after an initial upfront payment of ₹2.43 Cr. Furthermore, the statutory auditors issued an adverse opinion, highlighting that the lender auctioned the entire plant and machinery on May 18, 2026, for ₹3.82 Cr, creating severe going-concern risk.
Confidence: HIGH
What changedSRPL posted another quarter of zero operational revenue while confirming that its main manufacturing assets were auctioned off by its secured lender following an OTS default.
Why it mattersThe auction of all plant and machinery and acute liquidity distress indicate a halt in core processing activities and heightened risk of insolvency.
Net Loss (Q1 ended Jun 2026): ₹6.36 CrRevenue from Operations: ₹0.00Plant & Machinery Auction Realization: ₹3.82 CrDefaulted OTS Installments: ₹22.33 CrFinance Costs (Q1): ₹7.21 Cr
📅 Short termNegative outlook expected due to the adverse auditor opinion, operational shutdown, and unresolved defaults.
📈 Long termViability as a going concern is critically impaired following the disposal of core productive assets and heavy debt burden.
⚠ Risk flags
- Loss of primary manufacturing assets via bank auction
- Default on bank loan OTS and statutory dues
- Adverse audit conclusion and material uncertainty on going concern
- Zero operational revenue
Key Highlights
Revenue from operations was ₹0 Cr, with a net loss of ₹6.36 Cr (Rs 636.40 lakhs) for Q1 ended June 30, 2026.
Union Bank of India auctioned the company's entire plant and machinery on May 18, 2026, for ₹3.82 Cr (Rs 382.00 lakhs).
Company defaulted on OTS commitments, failing to pay the second installment of ₹3.76 Cr and the final installment of ₹18.56 Cr.
Finance costs rose sharply to ₹7.21 Cr (Rs 720.57 lakhs) during the quarter.
Auditors issued an adverse conclusion citing non-compliance with Ind AS 1 for going concern and inability to verify inventory and fixed assets.
👀 What to Watch
Track further regulatory filings regarding legal or insolvency proceedings, potential debt resolution steps, and any plans for equity restructuring.
₹17 Cr Asset Sale: SRPL Seeks Shareholder Approval to Sell Main Undertaking
Shree Ram Proteins Limited (SRPL) has issued a postal ballot notice seeking shareholder approval to sell its primary undertaking, including land and machinery at Rajkot, for approximately ₹17 crore. This transaction is critical as the company currently reports zero TTM revenue and carries a debt of ₹37 crore. The proposed sale value of ₹17 crore represents roughly 121% of the company's current market capitalization of ₹14 crore. Proceeds are intended for debt repayment and working capital to address the company's severe liquidity crunch.
Confidence: HIGH
What changedThe company is re-attempting to sell its core manufacturing asset after a previous transaction failed, now seeking a broader mandate to sell to unidentified purchasers.
Why it mattersFor a company with zero revenue and a default rating, this asset sale is a survival necessity to settle outstanding loans and potentially restart operations.
Proposed sale value: ₹17.00 crSale value vs Market Cap: ~121%Total Debt: ₹37 crTTM Revenue: ₹0 crPromoter Holding: 4.08%
📅 Short termThe stock may experience volatility during the 30-day voting period as the market assesses the likelihood of a successful debt reduction.
📈 Long termHighly uncertain; while the sale reduces debt, it involves disposing of the 'whole or substantially the whole' of the company's undertaking, leaving the future business model unclear.
⚠ Risk flags
- Extremely low promoter holding (4.08%)
- History of failed asset sale execution
- Disposal of core manufacturing assets
- High debt-to-equity ratio of 2.06
Key Highlights
Proposed sale of the undertaking for an aggregate consideration of approximately ₹17.00 crore
Sale value exceeds the current market capitalization of ₹14 crore by approximately 21%
Remote e-voting period scheduled from August 11, 2026, to September 09, 2026
Proceeds to be utilized for reducing the ₹37 crore debt and meeting working capital needs
Previous attempt to sell the same property to a related party (Sova Agrotech) was not executed
👀 What to Watch
Investors should monitor the e-voting results due by September 11, 2026, and watch for the identification of the final purchaser and the actual realization of sale proceeds.
Rs 17 Cr Sale of Undertaking Approved by Shree Ram Proteins Board
The Board of Shree Ram Proteins (SRPL) has approved the sale of its entire undertaking for an aggregate consideration of approximately Rs 17.00 crore. This move is significant as the company currently has a market capitalization of just Rs 14 crore and a total debt of Rs 37 crore. The company has reported zero revenue for the last four quarters and is in severe financial distress with a default rating. The sale is subject to shareholder approval via postal ballot and regulatory clearances.
Confidence: HIGH
What changedThe company has transitioned from seeking survival through preferential issues to proposing a sale of its primary business undertaking.
Why it mattersThis is a critical event for a company in default; the sale price is higher than the current market value but insufficient to cover total debt, suggesting significant remaining financial risk for equity holders.
Sale Consideration: Rs 17.00 CroreMarket Cap: Rs 14 CroreTotal Debt: Rs 37 CroreSale Value vs Market Cap: 121.4%Sale Value vs Total Debt: 45.9%
📅 Short termThe stock may see volatility as the market digests the Rs 17 crore valuation against the Rs 14 crore market cap, though the underlying debt crisis remains unresolved.
📈 Long termThe long-term outlook is highly uncertain as the company is selling its core undertaking; it effectively signals an exit from current operations to settle a portion of its liabilities.
⚠ Risk flags
- Proceeds (Rs 17 Cr) are significantly lower than total debt (Rs 37 Cr)
- Extremely low promoter holding of 4.08%
- Operational halt with zero revenue for over a year
- Default rating (IVR D) and liquidity crunch
Key Highlights
Proposed sale of the whole or substantially the whole undertaking for Rs 17.00 crore
Sale consideration represents approximately 121% of the current market capitalization of Rs 14 crore
Company carries a total debt of Rs 37 crore, meaning the sale proceeds cover only ~46% of total liabilities
TTM revenue remains at Rs 0 crore as operations have effectively halted due to liquidity constraints
Shareholder approval to be sought through a Postal Ballot process with remote e-voting
👀 What to Watch
Investors should monitor the Postal Ballot results and subsequent disclosures regarding the identity of the buyer and the specific plan for debt repayment. The primary concern remains whether the Rs 17 crore proceeds will be sufficient to prevent liquidation given the Rs 37 crore debt burden.
Rs 17.00 Cr Sale of Undertaking Approved by Shree Ram Proteins Board
The Board of Shree Ram Proteins (SRPL) has approved the sale or transfer of the company's entire undertaking for a consideration of approximately Rs 17.00 crore. This transaction is subject to shareholder approval via a Special Resolution through Postal Ballot. The proposed sale value represents approximately 121% of the company's current market capitalization (Rs 14 Cr) but covers less than half of its total debt (Rs 37 Cr). Given the company's TTM revenue of Rs 0 and ongoing financial distress, this move appears to be a critical attempt at debt settlement or liquidation.
Confidence: HIGH
What changedThe company has transitioned from a state of operational halt to a formal board-approved process for selling off its core business assets.
Why it mattersWith zero revenue and a debt-to-equity ratio of 2.06, the company is in severe financial distress; this sale is a terminal event for its current business structure and a primary step toward addressing defaults.
Sale Consideration: Rs 17.00 croreSale vs Market Cap: ~121%Total Debt: Rs 37 croreTTM Revenue: Rs 0 crorePromoter Holding: 4.08%
📅 Short termThe stock may experience volatility as the market digests the sale valuation relative to the market cap, though the underlying financial distress remains severe.
📈 Long termThe sale of the 'whole undertaking' suggests the company will cease its current solvent extraction operations, leading to either a total business pivot or eventual liquidation.
⚠ Risk flags
- Sale proceeds are insufficient to cover total debt of Rs 37 crore
- Zero operational revenue
- Extremely low promoter holding of 4.08%
- Default rating (IVR D) context
Key Highlights
Board approved the sale of the whole or substantially the whole undertaking for Rs 17.00 crore.
Proposed sale value of Rs 17.00 crore is ~121% of the current market capitalization of Rs 14 crore.
Company reported zero revenue for the last four consecutive quarters (TTM Revenue: Rs 0).
Total debt of Rs 37 crore significantly exceeds the proposed sale consideration of Rs 17 crore.
Ms. Payal Dhamecha has been appointed as the Scrutinizer for the Postal Ballot process.
👀 What to Watch
Investors should closely monitor the upcoming Postal Ballot notice for details on the buyer and the specific assets included in the 'undertaking'. The key factor to watch is how the Rs 17 crore proceeds will be distributed among creditors, given the Rs 37 crore debt pile.
SRPL Faces Adverse Audit Opinion and Insolvency Proceedings for FY25
Shree Ram Proteins Limited (SRPL) has received an 'Adverse Opinion' from its auditors for the financial year ended March 31, 2025, indicating the financial statements do not provide a true and fair view. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the IBC 2016 due to defaults on loans and statutory dues. Financial performance has collapsed, with FY25 revenue at Rs 0.0 Cr and a net loss of Rs 21.08 Cr. Auditors highlighted a total lack of physical verification for inventories and fixed assets, alongside missing balance confirmations for debtors and creditors.
Confidence: HIGH
What changedThe company provided a formal response to NSE's clarification request, confirming that its auditors have issued an adverse opinion and that the company is officially in insolvency proceedings.
Why it mattersThis confirms the company is in severe financial distress with no operational revenue and is unable to meet its debt obligations of Rs 37 Cr, placing the equity at risk of total loss in a restructuring or liquidation scenario.
FY25 Revenue: Rs 0.0 crFY25 Net Loss: Rs -21.08 crTotal Debt: Rs 37 crDebt to Market Cap Ratio: 2.64xPromoter Holding: 4.08%
📅 Short termThe stock is likely to remain under extreme pressure or face trading restrictions due to the adverse audit opinion and ongoing insolvency proceedings.
📈 Long termThe long-term outlook is highly uncertain and depends entirely on the outcome of the CIRP; typical outcomes in such cases involve significant equity dilution or liquidation.
⚠ Risk flags
- Insolvency proceedings (CIRP)
- Adverse Audit Opinion
- Zero operational revenue
- Default on loans and statutory dues
- Extremely low promoter holding
Key Highlights
Auditors issued an Adverse Opinion for FY25, stating financial results do not represent a true and fair view.
Company is under Corporate Insolvency Resolution Process (CIRP) as per Note 8 of the financial results.
Reported Rs 0.0 Cr revenue for FY25, compared to Rs 14.77 Cr in FY24.
Total debt of Rs 37 Cr significantly exceeds the current market capitalization of Rs 14 Cr.
Promoter holding remains critically low at 4.08% as of March 2026.
👀 What to Watch
Investors should closely monitor NCLT updates regarding the Corporate Insolvency Resolution Process (CIRP) as the company faces a high risk of liquidation. The adverse audit opinion suggests that the reported financial figures may not be reliable for valuation purposes.
SRPL Submits Pending Annual Reports for FY24 & FY25; Requests Revocation of Trading Suspension
Shree Ram Proteins Limited (SRPL) has completed the submission of its Annual Reports for two consecutive financial years, FY 2023-24 and FY 2024-25, via the NEAPS portal on February 11, 2026. This action follows a suspension notice from the NSE dated December 30, 2025, triggered by non-compliance with Regulation 34 of SEBI (LODR) Regulations. The company is also filing a compounding petition under Section 441 of the Companies Act for delays in holding its Annual General Meetings. SRPL has formally requested the exchange to revoke the suspension of trading in its securities following these filings.
Key Highlights
Submitted pending Annual Reports for FY 2023-24 and FY 2024-25 on February 11, 2026
Addressed NSE suspension notice (Ref: NSE/LIST/C/2025/13391) regarding non-compliance
Initiated compounding petition under Section 441 for delays in holding AGMs for the specified years
Formally requested NSE to revoke the suspension of trading in the company's securities
👀 What to Watch
Investors should wait for official confirmation from the NSE regarding the revocation of the trading suspension before making any decisions. The history of significant compliance delays and the need for legal compounding suggest a high-risk profile for this stock.
Shree Ram Proteins to Sell Land Undertaking for ₹30 Crore to Sova Agrotech
Shree Ram Proteins Limited (SRPL) has received shareholder approval to sell its land undertaking in Gondal, Rajkot, for a total consideration not exceeding ₹30 Crore. The sale is being made to Sova Agrotech Private Limited, a related party, with the transaction expected to be completed by April 2026. The company aims to use the proceeds to streamline its asset base, reduce maintenance costs, and focus on core business operations. The disposal was approved via a special resolution during the Extra Ordinary General Meeting held on March 5, 2026.
Key Highlights
Sale of land situated at Gondal, Rajkot for a consideration of up to ₹30 Crore.
Transaction is with Sova Agrotech Private Limited, a related party involving promoter Ms. Geetaben Lalitbhai Vasoya.
Expected completion date for the sale/disposal is set for April 2026.
Shareholder approval obtained via special resolution at the EGM held on March 5, 2026.
Strategic rationale includes streamlining assets and focusing on core business operations.
👀 What to Watch
Investors should track the actual receipt of the ₹30 Crore and how the management redeploys this capital into core operations. Given it is a related party transaction, verify that the final valuation aligns with independent market benchmarks.
Shree Ram Proteins Shareholders Approve Asset Sale and QIP Capital Raise
Shree Ram Proteins Limited (SRPL) has received shareholder approval for two critical resolutions during its EOGM held on March 05, 2026. The first resolution, involving the sale of a company undertaking as a material related party transaction, passed with 100% of the 16,448,040 votes in favor. The second resolution authorizes the company to raise capital through a Qualified Institutions Placement (QIP), which was approved by a 99.91% majority. These approvals provide the company with the mandate to restructure its assets and seek fresh institutional investment.
Key Highlights
100% shareholder approval for the sale of a company undertaking as a material related party transaction involving 16,448,040 votes.
99.91% majority (16,436,640 votes) in favor of raising capital via Qualified Institutions Placement (QIP).
Total of 54 members participated in the electronic voting process representing 16,448,040 shares.
The QIP resolution saw minimal opposition, with only 15,000 votes (0.09%) cast against it.
👀 What to Watch
Investors should monitor the pricing and dilution impact of the upcoming QIP and the specific terms of the asset sale. The high approval rate suggests strong alignment between participating shareholders and management's strategic restructuring plans.
Shree Ram Proteins Reports Zero Revenue and ₹21.07 Cr Net Loss in FY25; Issues AGM Addendum
Shree Ram Proteins Limited (SRPL) has issued a corrigendum and addendum to its 17th Annual Report and AGM notice, primarily to include the missing Secretarial Audit Report and correct director re-appointment details. The company's financial health has deteriorated severely, with revenue from operations falling to zero in FY 2024-25 compared to ₹1,476.60 Lakhs in the previous year. Net loss has more than doubled to ₹2,107.51 Lakhs, driven by the total halt in operations. The company is currently attempting to raise up to ₹49 Crores through a Rights Issue to stabilize its position.
Key Highlights
Revenue from operations dropped 100% to zero in FY 2024-25 from ₹1,476.60 Lakhs in FY 2023-24.
Net loss widened significantly to ₹2,107.51 Lakhs for the year ended March 31, 2025.
Corrigendum issued to correct the director retiring by rotation from Mr. Ravindra Kumar Singh to Mr. Piyush Vasoya.
Secretarial Audit Report for FY 2024-25 (pages 71-91) added as an addendum to the Annual Report.
Company is pursuing a Rights Issue of up to ₹49 Crores and a preferential allotment of 5 crore shares.
👀 What to Watch
Investors should be highly concerned by the total cessation of operational revenue and the widening losses; the stock remains a high-risk speculative play contingent on the success of the proposed fundraise.
Shree Ram Proteins Reports Zero Revenue in FY25; Issues AGM Corrigendum for Director Re-appointment
Shree Ram Proteins Limited (SRPL) has issued a corrigendum to its 17th AGM notice, correcting the director retiring by rotation to Mr. Piyush Vasoya and adding the missing Secretarial Audit Report. The company's financial performance for FY 2024-25 reveals a total collapse in operations, with revenue from operations falling to zero from ₹1,476.60 Lakhs in the previous year. Consequently, the net loss widened significantly to ₹2,107.51 Lakhs compared to a loss of ₹958.48 Lakhs in FY 2023-24. The board has skipped dividends to conserve capital amid these severe operational challenges.
Key Highlights
Revenue from operations plummeted to zero in FY 2024-25 from ₹1,476.60 Lakhs in FY 2023-24.
Net loss for the year widened to ₹2,107.51 Lakhs, more than doubling from the previous year's loss of ₹958.48 Lakhs.
EBITDA stood at a negative ₹1,693.77 Lakhs, reflecting severe operational distress and lack of business activity.
The company corrected its AGM notice to reflect the re-appointment of Mr. Piyush Vasoya instead of Mr. Ravindra Kumar Singh.
The Secretarial Audit Report for FY 2024-25 was added as an addendum after being omitted from the initial report.
👀 What to Watch
Investors should exercise extreme caution as the company has reported a total cessation of operational revenue and mounting losses. The lack of business activity suggests significant fundamental risks that require immediate clarification from management regarding the company's going concern status.
Shree Ram Proteins Reports Cessation of 3 Independent Directors Due to Delayed AGM
Shree Ram Proteins Limited (SRPL) has announced the cessation of three Additional Independent Directors effective February 5, 2026. The directors, Ms. Naaz Jaiswal, Mr. Akash Sureshbhai Gajera, and Mr. Yogeshbhaichandubhai Dhanani, have vacated their offices due to the company's failure to hold its Annual General Meeting (AGM) within the statutory due date. This automatic cessation is mandated under Section 161(1) of the Companies Act, 2013, which requires additional directors to step down on the date the AGM should have been held. This development highlights a significant lapse in corporate governance and regulatory compliance.
Key Highlights
Cessation of 3 Additional Independent Directors effective from February 5, 2026.
Directors involved are Ms. Naaz Jaiswal, Mr. Akash Sureshbhai Gajera, and Mr. Yogeshbhaichandubhai Dhanani.
The cessation resulted from the company's failure to conduct its Annual General Meeting (AGM) within the statutory timeline.
Action taken in accordance with Section 161(1) of the Companies Act, 2013.
The vacancy of three independent directors simultaneously may affect board composition and committee requirements.
👀 What to Watch
Investors should exercise caution as the failure to hold an AGM on time is a red flag regarding internal controls and regulatory compliance. Monitor the company's next steps for appointing new directors and scheduling the overdue AGM.
SRPL to Raise ₹100 Cr and Acquire Stake in Sova Agrotech for ₹30 Cr
Shree Ram Proteins Limited (SRPL) has approved a major fundraising plan of up to ₹100 Crores through equity or convertible securities. A significant portion of these funds, up to ₹30 Crores, is designated for acquiring a controlling stake in Sova Agrotech Private Limited, which is currently settling debts with Union Bank. The company also approved the sale of its land in Rajkot and is undergoing a major board restructuring with four new director appointments. Notably, the company is clearing a backlog of compliance by scheduling its 15th and 16th AGMs simultaneously in March 2026.
Key Highlights
Approved fundraising of up to ₹100 Crores via preferential issue, rights issue, or other equity-linked instruments.
Proposed acquisition of a controlling stake in Sova Agrotech Private Limited for ₹30 Crores.
Sova Agrotech to acquire land, plant, and machinery for ₹24.75 Crores via a One Time Settlement (OTS) with Union Bank of India.
Approved the sale of company-owned land at Bhunava, Rajkot, subject to shareholder approval.
Scheduled the 15th AGM (FY24), 16th AGM (FY25), and an EGM all for March 5, 2026, to address pending regulatory matters.
👀 What to Watch
Investors should be cautious as the company is holding AGMs for 2024 and 2025 in 2026, indicating significant past compliance delays. Monitor the specific terms of the ₹100 Crore fundraise and the valuation details of the Sova Agrotech acquisition before committing capital.
